tetraethylammonium has been researched along with Epilepsy in 15 studies
Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aksoz, E | 1 |
| Sara, Y | 1 |
| Onur, R | 1 |
| Kherani, ZS | 1 |
| Auer, RN | 1 |
| SALTER, WT | 1 |
| Rüschenschmidt, C | 2 |
| Köhling, R | 2 |
| Schwarz, M | 1 |
| Straub, H | 2 |
| Gorji, A | 2 |
| Siep, E | 2 |
| Ebner, A | 1 |
| Pannek, HW | 1 |
| Tuxhorn, I | 1 |
| Wolf, P | 1 |
| Speckmann, EJ | 2 |
| Yan, HD | 1 |
| Ishihara, K | 1 |
| Hanaya, R | 1 |
| Kurisu, K | 1 |
| Serikawa, T | 1 |
| Sasa, M | 1 |
| Chinestra, P | 1 |
| Leinekugel, X | 1 |
| Ben Ari, Y | 1 |
| Pollard, H | 1 |
| Fueta, Y | 1 |
| Avoli, M | 1 |
| Thorin, E | 1 |
| Nguyen, TD | 1 |
| Bouthillier, A | 1 |
| Gutschmidt, KU | 1 |
| Stenkamp, K | 2 |
| Buchheim, K | 2 |
| Heinemann, U | 2 |
| Meierkord, H | 2 |
| Bikson, M | 1 |
| Ghai, RS | 1 |
| Baraban, SC | 2 |
| Durand, DM | 1 |
| Jow, F | 1 |
| Wang, K | 1 |
| Castro, PA | 1 |
| Cooper, EC | 1 |
| Lowenstein, DH | 1 |
| Schuchmann, S | 1 |
| Breustedt, J | 1 |
| Windmüller, O | 1 |
| Rutecki, PA | 1 |
| Lebeda, FJ | 1 |
| Johnston, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment Efficacy of 1-Octanol Compared to Placebo in Adults With Essential Tremor[NCT00080366] | Phase 2 | 14 participants | Interventional | 2004-03-31 | Completed | ||
| Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor[NCT00102596] | Phase 2 | 21 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Octanoic Acid is a metabolite of 1-octanol. Blood plasma levels of octanoic acid were measured at 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose. (NCT00102596)
Timeframe: 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose
| Intervention | ng/ml (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Octanoic Acid Level at 5 min post-dose | Plasma Octanoic Acid Level at 20 min post-dose | Plasma Octanoic Acid Level at 45 min post-dose | Plasma Octanoic Acid Level at 70 min post-dose | Plasma Octanoic Acid Level at 100 min post-dose | Plasma Octanoic Acid Level at 130 min post-dose | Plasma Octanoic Acid Level at 160 min post-dose | Plasma Octanoic Acid Level at 210 min post-dose | Plasma Octanoic Acid Level at 270 min post-dose | Plasma Octanoic Acid Level at 360 min post-dose | |
| 64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation | 62.94 | 5064.12 | 7967.97 | 6788.58 | 5701.60 | 5448.23 | 4662.88 | 3179.10 | 2248.74 | 1266.37 |
| 64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation | 74.16 | 3885.52 | 9645.55 | 13315.26 | 9289.39 | 9605.68 | 6678.69 | 4307.74 | 2618.25 | 872.51 |
(NCT00102596)
Timeframe: 0 minutes, 15 minutes, 100 minutes and 24 hours post-dose
| Intervention | beats per minute (Least Squares Mean) | |||
|---|---|---|---|---|
| Heart Rate at 0 min | Heart Rate at 15 min | Heart Rate at 100 min | Heart Rate at 24 hours | |
| 1-Octanol Dose | 70.8 | 66.6 | 67.1 | 72.4 |
Spirography mean tremor amplitudes were measured in the right hand of each participant at 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose. Then, the scores of each participant were normalized (i.e., divided by) by their baseline tremor severity scores so that all scores are expressed as a proportion of the baseline score. Therefore, 1 is the baseline tremor severity, and lower scores indicate tremor reduction. (NCT00102596)
Timeframe: 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose
| Intervention | normalized score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Normalized score at 0 minutes | Normalized score at 15 minutes post-dose | Normalized score at 30 minutes post-dose | Normalized score at 60 minutes post-dose | Normalized score at 90 minutes post-dose | Normalized score at 120 minutes post-dose | Normalized score at 150 minutes post-dose | Normalized score at 180 minutes post-dose | Normalized score at 240 minutes post-dose | Normalized score at 360 minutes post-dose | |
| 64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation | 1 | 1.009 | 0.826 | 0.786 | 0.670 | 0.662 | 0.680 | 0.645 | 0.791 | 0.894 |
| 64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation | 1 | 0.901 | 0.738 | 0.766 | 0.685 | 0.709 | 0.746 | 0.707 | 0.683 | 0.122 |
(NCT00102596)
Timeframe: 0 minutes, 15 minutes, 100 minutes and 24 hours post-dose
| Intervention | ms (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| PR Interval at 0 min | PR Interval at 15 min | PR Interval at 100 min | PR Interval at 24 hours | QTc Interval at 0 min | QTc Interval at 15 min | QTc Interval at 100 min | QTc Interval at 24 hours | |
| 1-Octanol Dose | 168.8 | 172.8 | 171.6 | 168.6 | 433.8 | 436.5 | 433.0 | 437.4 |
15 other studies available for tetraethylammonium and Epilepsy
| Article | Year |
|---|---|
T-type Ca
Topics: Animals; CA1 Region, Hippocampal; Calcium Channel Blockers; Calcium Channels, T-Type; Epilepsy; Long | 2020 |
Pharmacologic analysis of the mechanism of dark neuron production in cerebral cortex.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Artifacts; Biopsy; Brain Ischemia; Cerebral Cortex; D | 2008 |
Therapeutics and toxicology.
Topics: Anemia; Anemia, Pernicious; Antacids; Anti-Bacterial Agents; Arthritis; Arthritis, Rheumatoid; Blood | 1950 |
Characterization of a fast transient outward current in neocortical neurons from epilepsy patients.
Topics: Adolescent; Adult; Anesthetics, Local; Anti-Arrhythmia Agents; Cadmium; Child, Preschool; Epilepsy; | 2004 |
Reduction of human neocortical and guinea pig CA1-neuron A-type currents by organic calcium channel blockers.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Animals; Calcium Channel Blockers; Child; Epilepsy; Fem | 2004 |
Voltage-dependent calcium channel abnormalities in hippocampal CA3 neurons of spontaneously epileptic rats.
Topics: Action Potentials; Animals; Calcium; Calcium Channels; Epilepsy; Fluoresceins; Hippocampus; Membrane | 2007 |
Use of hippocampal slices to study mRNA changes in relation to synaptic plasticity.
Topics: Animals; Base Sequence; DNA-Binding Proteins; Early Growth Response Protein 1; Electric Stimulation; | 1994 |
Tetraethylammonium-induced epileptiform activity in young and adult rat hippocampus.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Aging; Animals; Bicuculline; Dose-Response Relationship, Drug; | 1993 |
Control of vascular tone by endogenous endothelin-1 in human pial arteries.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Arteries; Brain Neoplasms; Cerebral Cortex; Endothelin | 1998 |
Anticonvulsant actions of furosemide in vitro.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anticonvulsants; Calcium; Electric Stimulation; Entorhi | 1999 |
Modulation of burst frequency, duration, and amplitude in the zero-Ca(2+) model of epileptiform activity.
Topics: 4-Aminopyridine; Animals; Barium; Calcium; Calibration; Cesium; Electric Stimulation; Epilepsy; Evok | 1999 |
Modulation of burst frequency, duration, and amplitude in the zero-Ca(2+) model of epileptiform activity.
Topics: 4-Aminopyridine; Animals; Barium; Calcium; Calibration; Cesium; Electric Stimulation; Epilepsy; Evok | 1999 |
Modulation of burst frequency, duration, and amplitude in the zero-Ca(2+) model of epileptiform activity.
Topics: 4-Aminopyridine; Animals; Barium; Calcium; Calibration; Cesium; Electric Stimulation; Epilepsy; Evok | 1999 |
Modulation of burst frequency, duration, and amplitude in the zero-Ca(2+) model of epileptiform activity.
Topics: 4-Aminopyridine; Animals; Barium; Calcium; Calibration; Cesium; Electric Stimulation; Epilepsy; Evok | 1999 |
Cloning and functional expression of rKCNQ2 K(+) channel from rat brain.
Topics: Animals; Benzoquinones; Brain Chemistry; Cells, Cultured; Cloning, Molecular; Enzyme Inhibitors; Epi | 2000 |
Hippocampal heterotopia lack functional Kv4.2 potassium channels in the methylazoxymethanol model of cortical malformations and epilepsy.
Topics: 4-Aminopyridine; Action Potentials; Animals; Cerebral Cortex; Choristoma; Delayed Rectifier Potassiu | 2001 |
Synaptic and nonsynaptic ictogenesis occurs at different temperatures in submerged and interface rat brain slices.
Topics: Animals; Body Temperature; Brain; Calcium; Epilepsy; Hippocampus; Hydrogen-Ion Concentration; Magnes | 2002 |
Epileptiform activity in the hippocampus produced by tetraethylammonium.
Topics: Animals; Electric Stimulation; Electrodes; Epilepsy; Evoked Potentials; Hippocampus; In Vitro Techni | 1990 |